Cargando…

The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists

By February 2019, the Polish pharmaceutical industry, community and hospital pharmacies, wholesalers and parallel traders must all comply with the EU-wide Falsified Medicines Directive (FMD) legislation (2011/62/EU), to ensure that no medicinal product is dispensed to a patient without proper tracki...

Descripción completa

Detalles Bibliográficos
Autores principales: Merks, Piotr, Swieczkowski, Damian, Byliniak, Michal, Drozd, Mariola, Krupa, Katarzyna, Jaguszewski, Milosz, Brindley, David A, Naughton, Bernard D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750370/
https://www.ncbi.nlm.nih.gov/pubmed/29445453
http://dx.doi.org/10.1136/ejhpharm-2016-000970
_version_ 1783289708108840960
author Merks, Piotr
Swieczkowski, Damian
Byliniak, Michal
Drozd, Mariola
Krupa, Katarzyna
Jaguszewski, Milosz
Brindley, David A
Naughton, Bernard D
author_facet Merks, Piotr
Swieczkowski, Damian
Byliniak, Michal
Drozd, Mariola
Krupa, Katarzyna
Jaguszewski, Milosz
Brindley, David A
Naughton, Bernard D
author_sort Merks, Piotr
collection PubMed
description By February 2019, the Polish pharmaceutical industry, community and hospital pharmacies, wholesalers and parallel traders must all comply with the EU-wide Falsified Medicines Directive (FMD) legislation (2011/62/EU), to ensure that no medicinal product is dispensed to a patient without proper tracking and authentication. Here we describe how Poland is complying with the new EU regulations, the actions that have been taken to incorporate the FMD into Polish Pharmaceutical Law and whether or not these actions are sufficient. We found that Poland is only partially compliant with the FMD and further actions need to be undertaken to fully meet the Delegated Act (DA) requirements. Moreover, there is lack of awareness in Poland about the prevalence of falsified medication and the time scale required for implementation of the DA. Based on our findings, we suggest that a public awareness campaign should be started to raise awareness of the increased number of falsified medicines in the legal supply chain and that drug authorisation systems are implemented by Polish pharmacies to support the FMD.
format Online
Article
Text
id pubmed-5750370
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-57503702018-02-12 The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists Merks, Piotr Swieczkowski, Damian Byliniak, Michal Drozd, Mariola Krupa, Katarzyna Jaguszewski, Milosz Brindley, David A Naughton, Bernard D Eur J Hosp Pharm Review By February 2019, the Polish pharmaceutical industry, community and hospital pharmacies, wholesalers and parallel traders must all comply with the EU-wide Falsified Medicines Directive (FMD) legislation (2011/62/EU), to ensure that no medicinal product is dispensed to a patient without proper tracking and authentication. Here we describe how Poland is complying with the new EU regulations, the actions that have been taken to incorporate the FMD into Polish Pharmaceutical Law and whether or not these actions are sufficient. We found that Poland is only partially compliant with the FMD and further actions need to be undertaken to fully meet the Delegated Act (DA) requirements. Moreover, there is lack of awareness in Poland about the prevalence of falsified medication and the time scale required for implementation of the DA. Based on our findings, we suggest that a public awareness campaign should be started to raise awareness of the increased number of falsified medicines in the legal supply chain and that drug authorisation systems are implemented by Polish pharmacies to support the FMD. BMJ Publishing Group 2018-01 2016-07-27 /pmc/articles/PMC5750370/ /pubmed/29445453 http://dx.doi.org/10.1136/ejhpharm-2016-000970 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Review
Merks, Piotr
Swieczkowski, Damian
Byliniak, Michal
Drozd, Mariola
Krupa, Katarzyna
Jaguszewski, Milosz
Brindley, David A
Naughton, Bernard D
The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists
title The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists
title_full The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists
title_fullStr The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists
title_full_unstemmed The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists
title_short The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists
title_sort european falsified medicines directive in poland: background, implementation and potential recommendations for pharmacists
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750370/
https://www.ncbi.nlm.nih.gov/pubmed/29445453
http://dx.doi.org/10.1136/ejhpharm-2016-000970
work_keys_str_mv AT merkspiotr theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT swieczkowskidamian theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT byliniakmichal theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT drozdmariola theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT krupakatarzyna theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT jaguszewskimilosz theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT brindleydavida theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT naughtonbernardd theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT merkspiotr europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT swieczkowskidamian europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT byliniakmichal europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT drozdmariola europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT krupakatarzyna europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT jaguszewskimilosz europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT brindleydavida europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists
AT naughtonbernardd europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists